Risk Analysis: myths, confusions and real sense

Size: px
Start display at page:

Download "Risk Analysis: myths, confusions and real sense"

Transcription

1 Risk Analysis: myths, confusions and real sense Dr. Alexander Fedotov, Director of Invar-project Company, Moscow, Russia 1. What is risk analysis? 2. GMP EU and ICH Q9 promises 3. : comparisons of incomparable 4. Example for pharmaceuticals 5. Inspections and Delayed-action Mine Rational sense of risk analysis 2 What is Risk analysis? - Risk means the possibility of dangerous or unwanted event to occur; - People analyze risk for ages and every day to be protected against unwanted events; - Purpose is to understand chain: Reason Defect of tablet press punch, for example Event Break of punch Consequence for product Metal parts in the tablet 3 GMP EU and ICH Q9 promise : ICH Q9 Quality Risk Management ; : ICH Q9 became Annex 20 GMP EU; : it became Part III of GMP EU Introduction to GMP EU says: The aim of Part III is to clarify regulatory expectations and it should be viewed as a source of information on best current practices. 4 GMP EU and ICH Q9 promises Batch recall - Methods of risk managements are separated on general and other ; - General methods include: Flow charts; Check sheets; Cause and Effect diagram (Fishbone or Ishikawa diagram); and others. 5 Premises and equipment Quality control Documents Personnel Media Materials Process in Contaminants APIs Washing of vials WFI analysis Excipients Sterilizing of vials Mix-ups Vials Fault tree or Block-scheme 6 1

2 Example of Out-of-Specification Table Materials, process etc. Reason When/how it appeared 1 Materials - API Contamination July 20 Batch numbers recalled and actions Changing of supplier - excipients vials Damage of external March 20 The instruction was done to forwarding company packaging - stoppers caps Personal -contamination Wrong behavior May 20 The SOP was reviewed, secondary training and control of behavior -mistakes mixings Equipment 7 Washing of vials Vials Sterilizing of vials Process Materials Excipients API s WFI Media Contaminants Personnel Mix-ups Documents Quality control Premises and equipement in analysis Fishbone or Ishikawa diagram (offered in 1952) Product recall 8 EU GMP and ICH Q9 promise - Other methods include: FMEA, FMECA, HACCP and so on abbreviations. - Let s look how they work on example of FMEA (Failure Mode Effect Analysis) method that is propagated widely; - Others are similar. 9 It is stated that FMEA gives Quantity estimation of risk making following: 1st Step. All risks shall be grouped on evaluation criteria: - Severity/Impact (I); - Occurrence or estimation of probability of event (O); - Detectability (D). 10 2nd Step - Each of criteria has numerical value, - For example, numbers from 1 to 5, - 1 means the lowest risk and 5 means the highest risk. 3d Step - Risk Priority Number (RPN) is calculated by multiplying evaluation criteria: I O D; - RPN range is from 1 (when all criteria are 1) to 125 (when all criteria are 5); - RPN grows with increasing of risk

3 4th Step - Acceptance level of RPN shall be specified in advance; - It can be any number within RPN range (1-125), say, 27; 51 or 109; - It is assigned arbitrary, just by opinion of one or several persons. - If RPN < Acceptance level, then risk is low; - No further action needs to be implemented; - In contrary if RPN > Acceptance level, correction actions are needed FMEA has three fundamental mistakes: 1st mistake - Acceptance levels (and RPN) are assigned by human arbitrary or subjectively, by his own mind; -Thisarbitrary estimation serves further as a basis for responsible decision. It is a very dangerous approach! 15 FMEA: comparisons of incomparable 2nd mistake - Values with different sense (I; O; D) are multiplied; - result serves as a basis for conclusion; -To compare incomparable is a huge and obvious methodical mistake; - It is not possible to multiply values with different sense. 16 3d mistake - Arbitrary numbers are offered to estimate processes - evaluation criteria; - Mathematical play with RPN gives image of Quantity analysis only; - Arbitrary estimation whether RPN can be accepted or not. This play has nothing common with science FMEA Example: Two events for airplane Event Delay of plane arrival Crash of plane Severity Evaluation criteria Occurrence Detectability RPN Delay and Crash are equivalent by FMEA - Is it better than discussions of medieval monks from Thomas Aquinas times: How many devils can be accommodated on the tip of the needle?

4 Process step or equipment preparation preparation preparation Loading Automatic loading adjustment IPC Etc. FMEA - Example for pharmaceuticals Ac. Level=27 Possible failure/risk Cleaning not sufficient Recalibration interval violated Punches installed not correctly Consequence of failure Cross contamination/ microbiological contamination Occurrence Severity Detection RPN Further action Yes/No No No GMP conformity No Tablets contaminated (metal) machine defect, loss of production No Not enough No delivery of No loading goods granules for the compression process Wrong Patient dead No granules Wrong Tablet content too No Adjustment high, patient harm Balance wrong Wrong weight, Patient harm No ICH Q9 (Part III of EU GMP) says that it helps manufacture and inspector How it helps manufacture? - Does it help to construct process flow charts, to find critical points, to draw HVAC, WFI and other schemes? No! - They all shall be in the design! - To arrange routine testing/control and to write documents? But is already in GMP! 20 Risk analysis helps inspector How? One of inspectors writes: - Inspector has not enough time and cannot see all details; - Papers on risk analysis prepared by manufacturer make the inspector s task easier to understand work of the plant. Inspections and Delayed-action Mine It is a very important opinion: - Inspector observes not primary documents (WFI schemes, records, etc.); - but secondary ones, i.e. papers that reflect primary sources only partly; - prepared by persons to be inspected. A fundamental danger is hidden in this approach! Inspections and Delayed-action Mine It would be interesting to look: -How financial/tax inspector will check the company on interpretations of financial documents made by people under inspection, not on the very documents; -How road police will judge guilty drivers on driver s own interpretation of accident; - and so on. Inspections and Delayed-action Mine - Customer buys medicinal product that shall comply with primary documents not with exercises; - It cannot be allowed to evaluate manufacturer by extracts from documents or comments, especially made by persons under control. This is a Delayed-action Mine!

5 End of 1940s 1) New systems and their low reliability: - about 70 % Navy radio-electronic devices of US armed forces were inoperable because of malfunctions; - 50 % of equipment and spare-parts failed during storage in warehouses; -First computers could work without failure only a few hours/minutes. 25 2) Strong stress: - The Cold War and fear of global disaster; - But very responsible technical systems simply did not work; 3) It was a romantic period: Cybernetics and other sciences appeared. They planted trust that any problem can be solved with magic general methods without knowing it in-depth 26 - It is not a surprise that those who offered methods of solving all problems got immediate support; - They simply found themselves in right place and in right time; - Just a promise to solve problem ensured budgeting on trust only; - Risk analysis was among such applicants FMECA method was approved by US Ministry of Defense in 1947; - And high prestige of this Ministry started to work on methods of risk analysis; - Nobody noticed fundamental mistake of this method that compares incomparable. Start of cybernetics planted in mind seeds of hope that there can be general methods to analyze the problem without knowing it s - Risk analysis was widely discussed together with reliability and models; - As a result formal methods were rejected; - Problems shall be understood in-depth; - Facile or wrong advices are not needed. US Ministry of Defense cancelled FMECA in It is hardly believable that such Ministry could withdraw useful document s - Risk analysis businessmen understood that they have nothing to do in technical industries; - They came to food industry; - It was a great success for them; - Business to exploit trust of people in scientific-like methods gave great profit. 30 5

6 Pharmaceutical industry is the next; - We observe very well conducted company to occupy rich markets: - ICH Q9 information only, - Annex 20 GMP EU recommended, - Part III GMP EU more important. Pressure grows! 31 Risk analysis Danger of formal approach Why are we so anxious? -Time and human resources in real manufacturing life are always limited; - Plays with formal methods can distract attention from care on quality; - Methods can serve as excuse for risk It breaks the main condition: No risk for medicines is permitted! 32 Can Risk analysis can be positive? - Yes, if it professional, clear and useful. Example of Company Nutricia - In 1993 the batch of product contained residues of disinfectants was recalled from the market; - This accident pressed company to implement Risk analysis system. 33 Real sense of risk analysis is to show how facility is protected against (design): - Cross contamination (layouts; airflows; pressure differences; materials, personel etc. flow and so on); - Mixing of materials and products; - Mixing of sterile and non-sterile products; - Non-sterility in aseptic processes; - Contamination (particles, viables ); - Surfaces contamination; - design 34 Operation: Experience of Nutricia Thinking approach was applied that was focused on the sense of matter: - 36 risk analysis groups were arranged at the head factory; - 20 % of factory s personnel were members of these groups; - mean number of persons in group was 5; Experience of Nutricia - Weekly short meetings of each group; - Internal audits (self-inspections); - Analysis of customer s complaints; - Inspections of suppliers systematically; -Factory s data base on contamination was arranged and it is continually supported and revised

7 Experience of Nutricia Soon problematic places were revealed: - personnel; - contamination; - raw materials defects; - out-of-standards deviations. It is very close to problems of pharmaceutical factories. 37 Conclusion 1. Method has no right to exist in two cases: - if it is wrong and misleading for users; - if it gives trivial result (result that can be got by simpler way or is obvious). ICH Q9 methods fall under these two cases and are not suitable for use. 38 Conclusion 2. Special danger of methods enforced is that they allow unacceptable events. These methods, moving from the office to manufacture can be used by somebody to justify wrong work. 3. Science says that we belong to creatures named Homo sapience or Wise man. If so, why do we accept exercises like FMEA method? Conclusion 4. Everybody speaks about manufactures, inspectors and consultants. - What about customers, who the main party? - What can be their reaction on ICH Q9 and similar methods? 5. It is necessary to arrange wide discussion on Risk analysis methods with all pro and contra to form public opinion Thank you for your attention! 41 7

WHO guidelines on quality risk management

WHO guidelines on quality risk management Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating

More information

Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM

Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory

More information

Quality Risk Management

Quality Risk Management Quality Risk Management Audit Expectations and Observations Matthew Davis Lead Auditor Office of Manufacturing Quality, TGA CAPSIG 4 th May 2011 www.tga.gov.au 2 QRM - TGA Expectations and Observations

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.

More information

Risk Management from the Point of View of a Competent Authority

Risk Management from the Point of View of a Competent Authority Risk Management from the Point of View of a Competent Authority Rudolf Völler GMP Inspectorate, Regierungspräsidium, Darmstadt (Germany) Summary A working risk evaluation system is a key element of drug

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018

PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018 PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 045-1 1 July 2018 GUIDELINES ON THE FORMALISED RISK ASSESSMENT FOR ASCERTAINING THE APPROPRIATE GOOD MANUFACTURING

More information

CONTENTS 1 INTRODUCTION The Regulatory Focus on Quality Risk Management Objectives of Risk Assessment and Risk Management: The Key Concepts Key Terms in Relation to Risk and Risk Assessment Structure of

More information

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9 Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This

More information

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines

More information

Contents. Contents (13) 1 Production (23)

Contents. Contents (13) 1 Production (23) 1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing

More information

2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11.

2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11. LITERATURE REVIEW: Risk management is well known and practiced in many industries and several industry task forces have developed guidance documents that facilitate risk management. Risk management for

More information

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments

More information

Documenta tion and Records

Documenta tion and Records Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping

More information

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit. FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis

More information

Update to the Manufacturing Principles for Medicinal Products

Update to the Manufacturing Principles for Medicinal Products Update to the Manufacturing Principles for Medicinal Products Michel Lok, Head of Office Robyn Oatey, GMP Auditor, Medicines Office of Manufacturing Quality Therapeutic Goods Administration Introduction

More information

Prequalification of Medicines Programme

Prequalification of Medicines Programme Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General

More information

Introduction to Medicines Inspections Technical Updates:

Introduction to Medicines Inspections Technical Updates: Introduction to Medicines Inspections Technical Updates: GMP inspections of Active Pharmaceutical Ingrédients and Finished Pharmaceutical Products (including Reproductive Health Products) Vimal Sachdeva,

More information

Quality Assessment & GMP Similarities & Differences

Quality Assessment & GMP Similarities & Differences Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences

More information

Testo Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance

Testo Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries.

More information

Annex 4. Guidance on good manufacturing practices: inspection report. Background

Annex 4. Guidance on good manufacturing practices: inspection report. Background Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)

More information

Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected)

Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected) Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected) Karen McCullough MMI Associates (908) 534-6463 PDA Metro Chapter Day June 2, 2009 RISK is a four letter

More information

EU and FDA GMP Regulations: Overview and Comparison

EU and FDA GMP Regulations: Overview and Comparison THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational

More information

Inspection. Implementation of ICH Q8, Q9, Q10

Inspection. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory

More information

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013.

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013. GMP Inspection Deficiencies 2013 Review of Deficiencies Observed in 2013. Executive Summary The most frequently encountered defect categories raised over the previous five years have remained relatively

More information

PCI Pharmaceutical Consulting

PCI Pharmaceutical Consulting PCI Pharmaceutical Consulting The Role of the QP: before & after Annex 16 Presented by: Karen Ginsbury For IFF, Denmark March 2016 Responsibility Authority Responsibility Authority Having the duty to perform

More information

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline

More information

Systematic Risk Management: An Overview of ICH Q-9

Systematic Risk Management: An Overview of ICH Q-9 Systematic Risk Management: An Overview of ICH Q-9 March 12, 2014 12014 ParagonRx International LLC Today s Session Systematic Risk Management: An Overview of ICH Q-9 Speakers: Jeff Fetterman, President,

More information

Inspection Hot Topics

Inspection Hot Topics Inspection Hot Topics QP Forum, Trinity College Ciara Turley, Inspector, HPRA 16 th April 2015 Content Hot topics = common deficiencies Data based on 100 inspections conducted in 2014 Inspections of non-sterile

More information

Good manufacturing practices

Good manufacturing practices ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,

More information

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Guidelines for Process Validation of Pharmaceutical Dosage Forms Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical

More information

GMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel

GMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel GMP Manual GMP Manual 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C (1) 1.C.2 Documentation

More information

UNICEF Quality Assurance in the procurement of medicines

UNICEF Quality Assurance in the procurement of medicines UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen October 2008 Quality Assurance Centre SUPPLY DIVISION 2 Today s presentation addresses 3 questions: How do UNICEF manage quality

More information

Process development and basic GMP

Process development and basic GMP Process development and basic GMP Aulton Chapter 45, handouts Specification, stability, inprocess controls and validation Product development Process development Critical Product Qualities issues Critical

More information

ISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS

ISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS ISO 22000:2005 Standard Food Safety Management System INTERNATIONAL STANDARDS REGISTRATIONS 3.1 FOOD SAFETY concept that food will not cause harm to the consumer when it is prepared and/or eaten according

More information

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September

More information

Annex 14 WHO guidelines for drafting a site master file 136

Annex 14 WHO guidelines for drafting a site master file 136 World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix

More information

Risk Based Validation. Why, How and with what tools?

Risk Based Validation. Why, How and with what tools? Risk Based Validation Why, How and with what tools? Tech Talk Agenda History of FDA GMP initiative for the 21 st Century. Industry response to FDA initiative. Harmonisation through ICH. ASTM Standard on

More information

SITE MASTER FILE For MHRA

SITE MASTER FILE For MHRA ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of

More information

Unit 208 Assist with the manufacture and assembly of medicinal products

Unit 208 Assist with the manufacture and assembly of medicinal products Element 1 Element 2 Assist with the preparation and packaging Assist with the completion of the manufacturing and assembly process 341 342 Element 1 Element 2 Assist with the preparation and packaging

More information

18.H Questionnaire for preparing GMP-inspections

18.H Questionnaire for preparing GMP-inspections Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working

More information

CGMP for 21 st Century : A Risk-based Approach (Quality by Design)

CGMP for 21 st Century : A Risk-based Approach (Quality by Design) CGMP for 21 st Century : A Risk-based Approach (Quality by Design) Chung Keel Lee, Ph.D. Special Advisor to the Minister, MFDS Professor, EWU/SNU Advisor, WHO Chair, ISPE Korea 4Ms Four Basic Elements

More information

Paradigm Change in Manufacturing Operations SM

Paradigm Change in Manufacturing Operations SM Technical Report No. 54-3 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products

More information

Materials Management Traceability, CEPs and managing non-conforming sites

Materials Management Traceability, CEPs and managing non-conforming sites Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain

More information

Trotz sorgfältiger inhaltlicher Prüfung übernehmen wir keine Haftung für die Richtigkeit und Aktualität für Unterlagen von Dritten.

Trotz sorgfältiger inhaltlicher Prüfung übernehmen wir keine Haftung für die Richtigkeit und Aktualität für Unterlagen von Dritten. Trotz sorgfältiger inhaltlicher Prüfung übernehmen wir keine Haftung für die Richtigkeit und Aktualität für Unterlagen von Dritten. IFS HPC Issue 2 Joachim Mehnert Technical Director DQS CFS GmbH 23. February

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

Common deficiencies/ hot topics

Common deficiencies/ hot topics Common deficiencies/ hot topics Non-sterile & API manufacture Oisín Daly GMP Conference 7 February 2017 Dublin Non-sterile finished product manufacture Deficiencies by Eudralex Vol. 4 GMP guide > 60% 3

More information

Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp

Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp 2016 Regulatory Compliance Associates Inc. Top Observation for 5 years Year Drugs #1 citation Device #1 citation

More information

JFS-A/B/C Standards <Manufacturing> [Interpretations]

JFS-A/B/C Standards <Manufacturing> [Interpretations] JFS-A/B/C Standards [Interpretations] JFS-A Standard Ver. 1.1 JFS-B Standard Ver. 1.1 JFS-C Standard Ver. 2.2 Japan Food Safety Management Association September 15, 2017 Table of Contents

More information

COMPARING THE STANDARDS

COMPARING THE STANDARDS COMPARING THE STANDARDS Codex/NACMCF Preventive Rule BRC Comparison 2.0 FUNDAMENTAL Preparatory stages 1 - Assemble the team The team: ideally should be multidisciplinary can use outside expert help should

More information

Practical Strategies for Improving Quality Risk Management activities in GMP environments

Practical Strategies for Improving Quality Risk Management activities in GMP environments Practical Strategies for Improving Quality Risk Management activities in GMP environments Kevin O Donnell, Ph.D. Market Compliance Manager & Senior GMP Inspector, Irish Medicines Board, Ireland CMC Strategy

More information

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016 New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised

More information

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:

More information

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines

More information

Challenge H: For an even safer and more secure railway

Challenge H: For an even safer and more secure railway The application of risk based safety analysis has been introduced to the Railway system with the publication of the dedicated standard EN 50 126 in 1999. In the railway sector the application of these

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

The Role of Quality Risk Management in New Drug Development and Manufacturing

The Role of Quality Risk Management in New Drug Development and Manufacturing The Role of Quality Risk Management in New Drug Development and Manufacturing CASSS CMC Strategy Forum Bethesda, MD July 27, 2009 Terrance Ocheltree, RPh, PhD Pharmaceutical Assessment Lead (Acting) Office

More information

GAMP 4/5 Prospective / retrospective Qualification of water treatment plants) P. Dony

GAMP 4/5 Prospective / retrospective Qualification of water treatment plants) P. Dony GAMP 4/5 Prospective / retrospective Qualification of water treatment plants) P. Dony 31.03.2008 Table of contents Slide 2 1. GAMP 4 and GAMP 5 differences 2. CHRIST prospective Qualification strategy

More information

Overview of Regulatory Requirements for API and Formulations

Overview of Regulatory Requirements for API and Formulations Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed

More information

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Trinity College Dublin QP Forum 2017 Tuesday 25 th April Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current

More information

Quality Risk Management

Quality Risk Management Safeguarding public health Quality Risk Management Challenges and opportunities Ian Thrussell Strategy and Development Team GMP Inspection, I&S Division Ian.Thrussell@mhra.gsi.gov.uk Presentation overview

More information

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1 Quality Risk Management of the GDP Supply Chain Crowne Plaza Hotel, 25/2/2010 Dr Cormac Dalton Inspector Date 22-Feb-10 Slide 1 Supply Chain Experiment Pharmaceutical excipient ordered 3 rd December 09

More information

ROLE OF ICH GUIDELINES IN PHARMACEUTICAL QUALITY RISK MANGAMENT- REVIEW

ROLE OF ICH GUIDELINES IN PHARMACEUTICAL QUALITY RISK MANGAMENT- REVIEW ejpmr, 2016,3(7), 161-169. SJIF Impact Factor 3.628 Review Article EUROPEAN JOURNAL European OF PHARMACEUTICAL Journal of Pharmaceutical and Medical Research AND MEDICAL RESEARCH ISSN 2394-3211 www.ejpmr.com

More information

Checklist for the Auditor

Checklist for the Auditor Page: 1 / 17 Checklist for the Auditor Content done page Overview / Audit Elements 2-3 General Information 4-6 ACS (Audit Checklist STANDARD) P 3 7-12 Summary Corrective Actions 13-14 Possible Comments

More information

RISK ASSESSMENT IN PHARMACEUTICAL MICROBIOLOGY

RISK ASSESSMENT IN PHARMACEUTICAL MICROBIOLOGY RISK ASSESSMENT IN PHARMACEUTICAL MICROBIOLOGY Ivana Jovanovska-Klincarska 1*, Ilina Popovska 1, Vladimir Kostovski 1, Jelena Dimitrovska 1, Ema Kikovska-Stojanovska 1, Sonja Ugarkovic 1 1 Research and

More information

Robert Posgai Director of Materials Procurement, Biogen (BPOG)

Robert Posgai Director of Materials Procurement, Biogen (BPOG) Keynote Speaker Building the Foundations for Excellence in Biopharmaceutical Raw Material Supply Chain and Impact of Modality on Excipient Expectations Robert Posgai Director of Materials Procurement,

More information

MAINTENANCE the EU GMP COMPLIANCE: Internal and External Audit. Alessio Ferrari

MAINTENANCE the EU GMP COMPLIANCE: Internal and External Audit. Alessio Ferrari MAINTENANCE the EU GMP COMPLIANCE: Internal and External Audit Alessio Ferrari SUMMARY WHY COMPLIANCE for PHARMACEUTICAL? REGULATORY ENSURE and GUIDELINES INTERNAL INSPECTION SUPPLIERS ASSESSMENT and INSPECTION

More information

Drug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014

Drug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014 Drug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014 Copyright 2015 by FDAnews. All rights reserved. Photocopying or reproducing this report in any form, including electronic or facsimile

More information

Webinar Expert Module 3: GMP Inspections Dupont

Webinar Expert Module 3: GMP Inspections Dupont Webinar Expert Module 3: GMP Inspections Dupont 26 January & 9 February 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, trainer, coach

More information

Deficiencies found in Inspections and QP Responsibilities

Deficiencies found in Inspections and QP Responsibilities Deficiencies found in Inspections and QP Responsibilities Ciara Turley, HPRA Inspector QP Forum, Trinity College, Dublin 25 th April 2017 Dublin Key QP Responsibilities Chapter 1, 1.4 (xv) Medicinal products

More information

LG SOURCING VENDOR QUALITY MANAGEMENT SYSTEM REQUIREMENTS

LG SOURCING VENDOR QUALITY MANAGEMENT SYSTEM REQUIREMENTS LG SOURCING VENDOR QUALITY MANAGEMENT SYSTEM REQUIREMENTS LG Sourcing QMS ver01 03.29.2010 Page 1 of 16 PAGE INTENTIONALLY LEFT BLANK Copyright 2010, LF Corporation - All rights reserved No part of this

More information

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017 Strategies to Revise Quality Policy and Quality Objectives Eileen Cortes February 22, 2017 Agenda Elements of Compliance Quality Policy Outline Quality Strategy and Objectives Case Study Open Discussion

More information

Enabling Improvement through the Product Lifecycle: Change Management within a PQS

Enabling Improvement through the Product Lifecycle: Change Management within a PQS Enabling Improvement through the Product Lifecycle: Change Management within a PQS Denise DiGiulio, Senior Advisor OPQ Office of Process and Facilities PDA Chapter Meeting Melbourne, Australia April 3,

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures

More information

Critical 0 Major 0 Minor 0. Certification Body name and address

Critical 0 Major 0 Minor 0. Certification Body name and address Audit Report Global Standard for Agents and Brokers Issue 1: January 2014 1.Audit Summary Company name BRC Site Code BRC Site code 2.Scope Operation Services Scope of audit Product categories Select Operation

More information

The ABCs and Challenges of GMP The American Experience

The ABCs and Challenges of GMP The American Experience The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine

More information

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference

More information

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards

More information

Process Capability and relationship to Quality management

Process Capability and relationship to Quality management Process Capability and relationship to Quality management Oct. 6, 2015 Barbara Allen, Ph.D. Global Quality Systems Eli Lilly and Company Core Objective Safely & reliably manufacture quality medicines for

More information

Impact and management tool for identification and reduction of human Errors in pharmaceuticals Industry

Impact and management tool for identification and reduction of human Errors in pharmaceuticals Industry 7 Impact and management tool for identification and reduction of human Errors in pharmaceuticals Industry Suleman S. khoja 1 *, Sohil S. khoja 1, Farhad S. Khoja 2, Shamim Khoja 2, Narmin Pirani 2 1 Resource

More information

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies Case Study Title: Defining Process Design Space Case No. RMWG-07 GMP System Impacted: Introduction / Background

More information

Complaints Investigations Root Cause Analysis

Complaints Investigations Root Cause Analysis Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, 6 February 2014 SANCO/TSE/ The received contributions together with the identity of

More information

Opportunities, Challenges and Benefits of using HACCP as a Quality Risk Management Tool in the Pharmaceutical Industry

Opportunities, Challenges and Benefits of using HACCP as a Quality Risk Management Tool in the Pharmaceutical Industry Opportunities, Challenges and Benefits of using HACCP as a Quality Risk Management Tool in the Pharmaceutical Industry Saurabh Dahiya 1,, Roop K. Khar 1 and Aruna Chhikara 2 1 Department of Pharmaceutics,

More information

PROCESS VALIDATION ANSM 2015 FDA 2011

PROCESS VALIDATION ANSM 2015 FDA 2011 PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104

More information

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE September/October 2008, Vol. 28 No. 5 This executive summary provides an overview of the second edition of the ISPE Baseline Guide:

More information

GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS. (Made under section 122(1)(o))

GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS. (Made under section 122(1)(o)) GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS (Made under section 122(1)(o)) THE TANZANIA FOOD, DRUGS AND COSMETICS (GOOD MANUFACTURING PRACTICE ENFORCEMENT)

More information

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

More information

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended

More information

Version No. Prepared by Date of prepared Approved by Date of approval

Version No. Prepared by Date of prepared Approved by Date of approval Co., Ltd. Plant Site Master File Document No. xx-xx Version No. Prepared by Date of prepared Approved by Date of approval 1 Table of Contents 1 General information on the manufacturer 1.1 Contact information

More information

API EUROPEAN GMP REQUIREMENTS. Alessio Ferrari

API EUROPEAN GMP REQUIREMENTS. Alessio Ferrari API EUROPEAN GMP REQUIREMENTS Alessio Ferrari SUMMARY GUIDELINES IMPLICATIONS FOR THE INDUSTRY ARTICLE 46 (F) OF DIRECTIVE 2001/83/EC PART I EU GMP Chapter 5 OFFICIAL MEASURES TO PROTECT. PROCEDURE TO

More information

MEDICAL DEVICES. Medical Device Manufacturing License. Facility Layout Design as per various regulatory requirements. Clean room and HVAC consultation

MEDICAL DEVICES. Medical Device Manufacturing License. Facility Layout Design as per various regulatory requirements. Clean room and HVAC consultation MEDICAL DEVICES With more than 100,000 individual medical devices on the market, patients have access to an astonishing array of products that can improve health and extend life. But the safety concerns

More information

Joint WQHO/UNICEF/UNFPA suppliers meeting

Joint WQHO/UNICEF/UNFPA suppliers meeting Joint WQHO/UNICEF/UNFPA suppliers meeting Pre-qualification of male latex condoms Tuesday 24 th November 2015 David Hill David Hill and Associates Pre-qualification of manufacturing sites UNFPA inspector

More information

Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products

Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products March 2014 Table of Content INTRODUCTION 3 Section 1: GENERAL RESPONSIBILITIES OF HOLDER

More information

Supply Chain Supplier Quality Management. Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District

Supply Chain Supplier Quality Management. Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District Supply Chain Supplier Quality Management Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District 1 Overview Product Life Cycle Maintaining Quality in Supply Chain FDA and ICH Guidances

More information

Packaging Operations Technical Subcommittee

Packaging Operations Technical Subcommittee and Sterile About the Presenter John Derek Thompson Lead Sterile Engineer, DePuy Synthes Certified Professional with the IOPP Member of the Medical Device Technical Committee Chairman of the Member of

More information

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern

More information